Cannabis Cocktails and the Changing Beverage Landscape with Paul Weaver

Cannabis Cocktails and the Changing Beverage Landscape with Paul Weaver

Author: Cannabis Radio February 26, 2025 Duration: 45:27

Paul Weaver, Director of Cannabis at the Boston Beer Company, shared insights into the company's Canadian Cannabis Division and their new product, Emerald Hour, a line of non-alcoholic cannabis cocktails designed for experienced consumers seeking a full-spectrum, solventless experience.

 The product launch strategy, focusing initially on the Ontario market due to its regulatory landscape, was discussed, along with plans for US expansion. The conversation highlighted the growing trend of consumers, particularly younger generations, shifting away from alcohol and towards cannabis-infused beverages, a phenomenon sometimes referred to as "cali sober." 

This demographic shift is driving innovation in the cannabis beverage sector, with companies like Boston Beer Company adapting to these changing preferences. The discussion also touched upon the challenges and opportunities within the Canadian cannabis market, including regulatory hurdles and the growth of cannabis-infused beverages. The potential of cannabis beverages as a healthier alternative to alcohol, with faster onset times and better control over effects, was explored, along with the increasing awareness of the health risks associated with alcohol consumption. 

The conversation concluded with a discussion of the challenges of expanding cannabis products into the fragmented US market, the importance of scale, and the potential for significant growth in the cannabis beverage market over the next decade.



Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy

There’s a lot more to the cannabis industry than what grows in the field. Blunt Business, from Cannabis Radio, digs into the complex reality of building and running a company in this fast-moving space. We’re talking about the real work behind the scenes-supply chain logistics, regulatory hurdles, branding in a crowded market, and managing teams in a unique cultural environment. Each episode brings together voices who are actually doing the job, from executives steering multi-state operations to entrepreneurs who just opened their first dispensary. You’ll hear candid roundtable discussions where strategies are debated, and interviews that get into the specifics of leadership and finance without the hype. This isn’t about advocacy or culture; it’s a practical look at the mechanics of a profitable, high-stakes business. Tune in for a podcast that cuts through the smoke and offers tangible insights you can apply, whether you’re an investor, a manager, or building your own venture from the ground up.
Author: Language: English Episodes: 100

Blunt Business
Podcast Episodes
A Psychedelic and Cannabis Research Revolution On the Horizon? [not-audio_url] [/not-audio_url]

Duration: 29:28
This episode of Blunt Business explores a significant shift in federal drug policy following a new executive order aimed at accelerating research into psychedelics like LSD, psilocybin, and ibogaine for treating mental h…
4/20 Fortune: Critics Say High-Stakes Holiday Losing Its Edge? [not-audio_url] [/not-audio_url]

Duration: 24:45
As the legal landscape evolves, the traditional 4/20 retail boom is showing signs of cooling, with some markets seeing higher sales during the surrounding week than on the holiday itself due to aggressive discounting and…
Inside New York’s Five-Year Cannabis Chronicle [not-audio_url] [/not-audio_url]

Duration: 29:51
In this episode of The Blunt Business, the discussion dives deep into the complex landscape of the New York cannabis market as it hits its five-year legalization anniversary. While Governor Kathy Hochul lauds the state’s…
The Cannabis Business CLIMB or Cannabis for Healthy Livers [not-audio_url] [/not-audio_url]

Duration: 17:24
Blunt Business dives into the shifting landscape of American cannabis, from the halls of Congress to the microscopic world of medical research. We break down the newly proposed CLIMB Act, a bipartisan bill aimed at final…